Key result
Intracoronary bradykinin cuts reperfusion noradrenaline release ~86% and reduces sustained VT in dogs.
Why the study?
The effects of intracoronary bradykinin infusion on noradrenaline release and ventricular arrhythmias following coronary occlusion and reperfusion were investigated.
Does intracoronary bradykinin infusion reduce noradrenaline release and ventricular arrhythmias following reperfusion of ischemic myocardium in anesthetized dogs?
Does intracoronary bradykinin infusion reduce noradrenaline release and ventricular arrhythmias following reperfusion of ischemic myocardium in anesthetized dogs?
Intracoronary bradykinin reduces cardiac noradrenaline release and protects against reperfusion-induced sustained ventricular tachycardia in a canine model of ischemia-reperfusion.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for bradykinin in reperfusion; leaves open translation to human practice.
OBJECTIVE: The aim of this study was to investigate the effects of intracoronary bradykinin (BK) infusion on noradrenaline release and ventricular arrhythmias induced by coronary occlusion and reperfusion in the anesthetized dog. METHODS: 14 anesthetized adult mongrel dogs of either sex underwent a 60 min occlusion of the left anterior descending coronary artery (LAD) followed by a 30-min reperfusion period. BK (1 ng.kg-1.min-1, n = 7), or its vehicle (Lactate Ringer, n = 7), infusions just distal to the left coronary ostium started 15 min before the LAD occlusion and were maintained throughout the experimental period. An epicardial vein, running parallel to the LAD was cannulated to enable the biochemical determinations. The effects of BK on ventricular arrhythmias, cardiac noradrenaline and lactate releases and creatine kinase activity were assessed. RESULTS: BK significantly reduced the amount of noradrenaline released at reperfusion by ischemic myocardium (from 82.1 +/- 31.7 to 11.9 +/- 9.6 ng.min-1), as well as plasma creatine kinase activity at 30 min of reperfusion. This is accompanied by a significant reduction in the incidence of reperfusion-induced sustained ventricular tachycardia. CONCLUSION: This suggests that the protective effect of bradykinin against reperfusion-induced sustained ventricular tachycardia could be associated with a reduction in cardiac noradrenaline release.
No takes yet. Share an insight, caveat, or question.
Ribuot et al. (1994) studied Ischemia-reperfusion injury (n=14). Intracoronary bradykinin vs. Lactate Ringer vehicle was evaluated on Amount of noradrenaline released at reperfusion. Intracoronary bradykinin infusion reduced noradrenaline release at reperfusion and the incidence of sustained ventricular tachycardia in dogs.
Synapse has enriched 10 related papers. Consider them for comparative context: